Funding for this research was provided by:
Instituto de Salud Carlos III (PI12/01775, PI16/01407, PI19/00245, RD16/0011/0015, RD16/0011/0004)
Consejería de Educación, Junta de Castilla y León (HUS308U14, CAS079P17, GRS1621/A/17, GRS1879/A/18, GRS1348/A/19)
Fundación Española de Hematología y Hemoterapia
Ministerio de Ciencia e Innovación (FPU18/03533)
Received: 1 September 2021
Accepted: 20 November 2021
First Online: 7 December 2021
: CD34<sup>+</sup> cells were isolated from 24 fresh UCB units obtained in the Obstetrics Department of the University Hospital of Salamanca following standard procedures, after informed consent was obtained from the corresponding mothers. For the in vivo studies, 6-week-old nonobese diabetic/severe combined immunodeficient mice (NOD/SCID; NOD.CB17-Prkdcscid/NcrCrl) were purchased from Charles River Laboratories (Barcelona, Spain) and maintained in the Animal Care Facility of the University of Salamanca. All procedures followed the Spanish and European Union guidelines (RD 1201/05 and 86/609/CEE) and were approved by the Bioethics Committee of the University of Salamanca (reg. 201600007333).
: Not applicable.
: The authors declare that they have no competing interests regarding the current manuscript.